Bruker Corporation $BRKR Shares Acquired by Candriam S.C.A.

Candriam S.C.A. lifted its stake in Bruker Corporation (NASDAQ:BRKR) by 69.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 642,990 shares of the medical research company’s stock after purchasing an additional 263,963 shares during the quarter. Candriam S.C.A. owned about 0.42% of Bruker worth $26,492,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its holdings in Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after buying an additional 487 shares in the last quarter. Allworth Financial LP boosted its position in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 364 shares during the last quarter. Huntington National Bank grew its holdings in shares of Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares during the period. Spire Wealth Management acquired a new stake in Bruker during the second quarter worth about $32,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after buying an additional 745 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 1.6%

Shares of NASDAQ BRKR opened at $41.79 on Friday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $6.35 billion, a PE ratio of 80.37, a PEG ratio of 5.31 and a beta of 1.26. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $64.64. The stock has a fifty day simple moving average of $35.83 and a 200-day simple moving average of $37.18.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. The company had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.Bruker’s revenue for the quarter was down .5% on a year-over-year basis. During the same period last year, the business posted $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, December 8th. Bruker’s dividend payout ratio is presently -125.00%.

Insider Buying and Selling

In other news, Director Cynthia M. Friend sold 3,535 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the sale, the director owned 18,016 shares of the company’s stock, valued at approximately $581,016. This represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John A. Ornell sold 6,233 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the sale, the director owned 35,212 shares in the company, valued at approximately $1,373,268. The trade was a 15.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 27.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BRKR. Barclays lifted their price target on shares of Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. TD Cowen lifted their target price on Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research report on Tuesday, November 4th. Wells Fargo & Company decreased their price target on Bruker from $50.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the stock a “hold” rating in a research report on Tuesday, August 5th. Finally, Cowen reaffirmed a “hold” rating on shares of Bruker in a research report on Tuesday, November 4th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $48.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.